Back to News
Market Impact: 0.1
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain
Source: prnewswire.com
Healthcare & Biotech
The article describes a potential first-in-class selective nociceptin receptor (NOP) agonist being developed to target moderate-to-severe acute pain. It provides no clinical results, timing, or other details on development progress.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- Why is Intuitive Surgical stock sliding today?
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Alpha Teknova stock tumbles on public offering announcement
- Disc Medicine prices $450 million stock offering at $75/share
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More
- AI Tools for Family Offices: A Stack by Decision Type